{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:10:51Z","timestamp":1777518651761,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011892","name":"Kaohsiung Chang Gung Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jmii.2025.06.010","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T11:18:12Z","timestamp":1751455092000},"page":"91-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of ten-day bismuth quadruple therapy for first-line anti-Helicobacter pylori infection in the elderly- A multicenter real-world report"],"prefix":"10.1016","volume":"59","author":[{"given":"Kuo-Hsuan","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Chen","family":"Tai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-Woey","family":"Tsay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pin-I","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deng-Chyang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song-Seng","family":"Loke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Chien","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8934-3223","authenticated-orcid":false,"given":"Seng-Kee","family":"Chuah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6614-5937","authenticated-orcid":false,"given":"Chih-Ming","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2025.06.010_bib1","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","article-title":"Kyoto global consensus report on Helicobacter pylori gastritis","volume":"64","author":"Sugano","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jmii.2025.06.010_bib2","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1056\/NEJMra020542","article-title":"Helicobacter pylori infection","volume":"347","author":"Suerbaum","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2025.06.010_bib3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc703","article-title":"Helicobacter pylori and gastrointestinal tract adenocarcinomas","volume":"2","author":"Peek","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jmii.2025.06.010_bib4","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1136\/gutjnl-2020-322368","article-title":"Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus","volume":"69","author":"Liou","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jmii.2025.06.010_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820976990","article-title":"Trend of changes in antibiotic resistance in Helicobacter pylori from 2013 to 2019: a multicentre report from Taiwan","volume":"13","author":"Liang","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.jmii.2025.06.010_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jmii.2025.06.010_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102529","article-title":"10-Day versus 14-day bismuth quadruple therapy for first-line eradication of Helicobacter pylori infection: a randomised, open-label, non-inferiority trial","volume":"70","author":"Yang","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.jmii.2025.06.010_bib8","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/0016-5085(90)90983-8","article-title":"Bismuth therapy in gastrointestinal diseases","volume":"99","author":"Gorbach","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jmii.2025.06.010_bib9","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1097\/MJT.0000000000000389","article-title":"Role of bismuth in the eradication of Helicobacter pylori","volume":"24","author":"Alkim","year":"2017","journal-title":"Am J Ther"},{"issue":"Suppl 1","key":"10.1016\/j.jmii.2025.06.010_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1365-2036.11.s1.13.x","article-title":"The actions of bismuth in the treatment of Helicobacter pylori infection","volume":"11","author":"Lambert","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jmii.2025.06.010_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-236929","article-title":"Salicylate toxicity from chronic bismuth subsalicylate use","volume":"13","author":"Halani","year":"2020","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jmii.2025.06.010_bib12","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12883-019-1437-9","article-title":"Bismuth encephalopathy- a rare complication of long-standing use of bismuth subsalicylate","volume":"19","author":"Borbinha","year":"2019","journal-title":"BMC Neurol"},{"key":"10.1016\/j.jmii.2025.06.010_bib13","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.3390\/antibiotics11121741","article-title":"Effects of bismuth exposure on the human kidney-A systematic review","volume":"11","author":"Pelepenko","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jmii.2025.06.010_bib14","series-title":"StatPearls. Treasure Island (FL)","article-title":"Bismuth subsalicylate","author":"Budisak","year":"2024"},{"key":"10.1016\/j.jmii.2025.06.010_bib15","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.14309\/ajg.0000000000002255","article-title":"Hybrid, high-dose dual and bismuth quadruple therapies for first-line treatment of Helicobacter pylori infection in Taiwan: a multicenter, open-label, randomized trial","volume":"118","author":"Hsu","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jmii.2025.06.010_bib16","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/gut.2003.022111","article-title":"Pylori antibiotic resistance: prevalence, importance, and advances in testing","volume":"53","author":"Megraud","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.jmii.2025.06.010_bib17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cgh.2009.09.030","article-title":"Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection","volume":"8","author":"Wu","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jmii.2025.06.010_bib18","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1523-5378.2012.00960.x","article-title":"The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin\/amoxicillin\/proton-pump inhibitor treatment--a pilot study","volume":"17","author":"Chuah","year":"2012","journal-title":"Helicobacter"},{"key":"10.1016\/j.jmii.2025.06.010_bib19","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1365-2362.2008.01951.x","article-title":"Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures","volume":"38","author":"Hsu","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jmii.2025.06.010_bib20","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1111\/j.1572-0241.2002.05977.x","article-title":"Clinical presentation in relation to diversity within the Helicobacter pylori cag pathogenicity island","volume":"97","author":"Hsu","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jmii.2025.06.010_bib21","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.2147\/IDR.S213998","article-title":"A comparison between dexlansoprazole modified release-based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication: a prospective randomized trial","volume":"12","author":"Tai","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jmii.2025.06.010_bib22","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/jcp.39.11.1279-a","article-title":"Simplified techniques for identifying Campylobacter pyloridis","volume":"39","author":"Gray","year":"1986","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jmii.2025.06.010_bib24","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0026-895X(25)09788-3","article-title":"Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese","volume":"46","author":"De Morais","year":"1994","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jmii.2025.06.010_bib25","doi-asserted-by":"crossref","first-page":"15419","DOI":"10.1016\/S0021-9258(17)40694-6","article-title":"The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans","volume":"269","author":"de Morais","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jmii.2025.06.010_bib26","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0009-9236(96)90214-3","article-title":"Genotyping of S-mephenytoin 4\u2019-hydroxylation in an extended Japanese population","volume":"60","author":"Kubota","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jmii.2025.06.010_bib27","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s005350170033","article-title":"Association of the interleukin-1 beta genetic polymorphism and gastric cancer risk in Japanese","volume":"36","author":"Kato","year":"2001","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jmii.2025.06.010_bib28","doi-asserted-by":"crossref","first-page":"514","DOI":"10.12998\/wjcc.v6.i12.514","article-title":"CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication","volume":"6","author":"Lin","year":"2018","journal-title":"World J Clin Cases"},{"issue":"4","key":"10.1016\/j.jmii.2025.06.010_bib29","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1053\/j.gastro.2023.12.022","article-title":"Global prevalence of Helicobacter pylori infection and incidence of gastric cancer between 1980 and 2022","volume":"166","author":"Chen","year":"2024","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jmii.2025.06.010_bib30","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12914","article-title":"Declining trends of prevalence of Helicobacter pylori infection and incidence of gastric cancer in Taiwan: an updated cross-sectional survey and meta-analysis","volume":"27","author":"Chen","year":"2022","journal-title":"Helicobacter"},{"key":"10.1016\/j.jmii.2025.06.010_bib31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1523-5378.2007.00518.x","article-title":"A report card to grade Helicobacter pylori therapy","volume":"12","author":"Graham","year":"2007","journal-title":"Helicobacter"},{"key":"10.1016\/j.jmii.2025.06.010_bib32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40266-022-00990-7","article-title":"Efficacy and safety of 7-day non-bismuth concomitant quadruple therapy for first-line Helicobacter pylori eradication in the elderly","volume":"40","author":"Ma","year":"2023","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jmii.2025.06.010_bib33","doi-asserted-by":"crossref","first-page":"7040","DOI":"10.3390\/jcm11237040","article-title":"Multiple bismuth quadruple therapy containing tetracyclines combined with other antibiotics and Helicobacter pylori eradication therapy","volume":"11","author":"Sun","year":"2022","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.jmii.2025.06.010_bib34","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1473-3099(19)30272-5","article-title":"Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial","volume":"19","author":"Liou","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jmii.2025.06.010_bib35","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41598-020-80802-3","article-title":"Gut microbiota changes related to Helicobacter pylori eradication with vonoprazan containing triple therapy among adolescents: a prospective multicenter study","volume":"11","author":"Kakiuchi","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jmii.2025.06.010_bib36","article-title":"The effects of probiotics supplementation on Helicobacter pylori standard treatment: an umbrella review of systematic reviews with meta-analyses","volume":"14","author":"Yang","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jmii.2025.06.010_bib37","article-title":"Comparative effectiveness of different probiotics supplements for triple helicobacter pylori eradication: a network meta-analysis","volume":"13","author":"Wang","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"issue":"20","key":"10.1016\/j.jmii.2025.06.010_bib38","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.12998\/wjcc.v11.i20.4740","article-title":"Probiotics and autoprobiotics for treatment of Helicobacter pylori infection","volume":"11","author":"Baryshnikova","year":"2023","journal-title":"World J Clin Cases"},{"issue":"1","key":"10.1016\/j.jmii.2025.06.010_bib39","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40121-020-00372-9","article-title":"The effect of probiotics supplementation on gut microbiota after Helicobacter pylori eradication: a multicenter randomized controlled trial","volume":"10","author":"Tang","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jmii.2025.06.010_bib40","doi-asserted-by":"crossref","first-page":"16029","DOI":"10.3748\/wjg.v20.i43.16029","article-title":"CYP2C19 polymorphism influences Helicobacter pylori eradication","volume":"20","author":"Kuo","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"Suppl","key":"10.1016\/j.jmii.2025.06.010_bib41","first-page":"S22","article-title":"CYP2C19 genotype and the PPIs--focus on rabeprazole","volume":"20","author":"Lim","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jmii.2025.06.010_bib42","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/cpt.2552","article-title":"Association of CYP2C19 polymorphism with proton pump inhibitors effectiveness and with fractures in real-life: retrospective cohort study","volume":"111","author":"Gronich","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jmii.2025.06.010_bib43","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/jgh.13233","article-title":"Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis","volume":"31","author":"Ichikawa","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jmii.2025.06.010_bib44","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1542-3565(03)00288-X","article-title":"Polymorphism of interleukin-1\u03b2 affects the eradication rates of Helicobacter pylori by triple therapy","volume":"2","author":"Furuta","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jmii.2025.06.010_bib45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.7150\/ijms.3.135","article-title":"Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A","volume":"3","author":"Ishida","year":"2006","journal-title":"Int J Med Sci"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118225001318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118225001318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:06:42Z","timestamp":1769832402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118225001318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1684118225001318"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2025.06.010","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of ten-day bismuth quadruple therapy for first-line anti-Helicobacter pylori infection in the elderly- A multicenter real-world report","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2025.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}